Tralokinumab for moderate-to-severe atopic dermatitis: A viable option for dupilumab nonresponders

Bibliographic Details
Published in:	JAAD International
Main Authors:	Christine T. Olagun-Samuel, BA, Christine C. Akoh, MD, PhD, Nnaemeka Anyanwu, BS, Elizabeth F. Sher, PhD, Carli D. Needle, BA, Jamie Widawsky, PA-C, MPAS, David E. Cohen, MD, MPH, Emily Milam, MD, Alexandra Flamm, MD, Vikash Oza, MD, Theodora K. Karagounis, MD, MS
Format:	Article
Language:	English
Published:	Elsevier 2026-02-01
Subjects:	atopic dermatitis biologic dupilumab tralokinumab
Online Access:	http://www.sciencedirect.com/science/article/pii/S266632872500121X

Internet